COVID-19 activity across the United States is currently at low levels. National hospitalizations are declining, and the CDC’s most recent modeling, as of June 16, 2026, estimates that infections are growing in only two states. Most of the country is experiencing a respiratory illness quiet period.
But the CDC is not declaring summer clear.
In its June 22, 2026 respiratory data update, the agency stated directly: “it remains possible that there could be larger increases this summer, particularly if a variant that the immune system no longer recognizes becomes more common.” The geographic focus of that concern is the South and West regions that experienced comparatively lower COVID-19 activity during the winter, leaving populations there with less recent immunity heading into the warmer months.
Why This Matters
Summer COVID surges are not a new pattern. They have been documented in previous years — particularly in the South and West, where scorching heat drives people indoors into air-conditioned spaces, creating the same concentrated indoor exposure conditions that drive respiratory transmission in winter.
This summer carries an additional variable: a heavily mutated COVID-19 variant called BA.3.2 (nicknamed “cicada”) has been detected in more than 30 states. According to virologists at Johns Hopkins, BA.3.2’s spike protein mutations may reduce the effectiveness of the 2025–2026 COVID vaccines in laboratory studies — though real-world data on its severity are still limited.
Both the World Health Organization and the CDC note that current COVID vaccines are still expected to provide meaningful protection against severe disease, even from newer variants.
What We Know So Far
The CDC’s epidemic trend modeling as of June 16, 2026 shows COVID infections growing or likely growing in two states, declining in 36 states, and not changing in 11. Overall, COVID-19 activity is characterized as low.
The warning about the South and West is based on population immunity patterns, not current transmission data. The CDC’s 2025–2026 respiratory season outlook explained the mechanism: the Northeast and Midwest experienced elevated winter COVID activity, building more recent immunity. The South and West did not. As summer brings people indoors and travel mixes populations, the regions with lower recent immunity face a higher susceptibility to spread.
Other respiratory viruses are also elevated nationally. The CDC’s June 22 update noted that parainfluenza virus is elevated nationwide, and human metapneumovirus and rhinovirus/enterovirus remain elevated but declining. Whooping cough is still circulating. The overall picture is a respiratory virus landscape with more activity than the midsummer low expected in prior years.
Where the Risk Is Highest
The CDC’s modeling framework identifies the South and West as the primary regions of concern for summer COVID activity. This includes the Southeast (Florida, Georgia, Texas, Louisiana, Alabama, Mississippi, Tennessee, the Carolinas) and the West (California, Arizona, Nevada, Oregon, Washington, Colorado).
Among those regions, major cities with large populations gathering indoors — in air-conditioned offices, restaurants, entertainment venues, and transit systems — carry the greatest practical risk. Atlanta, Houston, Dallas, Miami, Los Angeles, Phoenix, Las Vegas, and San Francisco are all in the geographic risk zone the CDC is flagging.
The World Cup 2026, which draws tens of millions of international visitors to U.S. host cities through July, adds a wildcard of international viral mixing to several of these metro areas simultaneously.
What Doctors and Experts Say
Virologists have characterized the current landscape as an early warning signal, not an alarm. The CDC’s framing is explicitly cautious and forward-looking. As of today, COVID-19 is not straining health care systems anywhere in the country.
The variant escape scenario — a new variant that the immune system no longer recognizes spreading widely — is a risk scenario based on modeling, not a prediction based on current surveillance data. “It’s not completely clear how effective the current vaccine will be [against BA.3.2], but it likely still has some effectiveness,” virologist Adolfo García-Sastre of the Icahn School of Medicine at Mount Sinai told NBC News.
Current COVID vaccines target the JN.1 lineage. The WHO and CDC both say those vaccines are expected to continue providing protection against severe disease from circulating variants.
What the Evidence Shows — and What It Does Not
This is a risk-based forecast, not a confirmed surge. The CDC’s statement is based on historical patterns and population immunity modeling, not a documented increase in hospitalizations or deaths. The agency is providing early situational awareness so individuals and health systems can prepare — not declaring an emergency.
The BA.3.2 variant is real and spreading, but it had not, as of April 2026, caused a major surge anywhere in the world despite its elevated immune-escape potential. Whether it gains dominance in the U.S. and whether it produces meaningfully more severe disease than current dominant variants remain open questions.
Who Faces the Greatest Risk?
For the potential summer increase, the highest-risk groups remain consistent with prior years:
- Adults 65 and older
- People with weakened immune systems, including those on immunosuppressive medications
- People with chronic lung, heart, or kidney disease
- People who have not been vaccinated or infected with COVID in the last six to 12 months
- People in the South and West with less recent COVID immunity
Younger, healthy adults face a much lower risk of severe illness, though they can still transmit the virus to higher-risk contacts.
Symptoms and Warning Signs to Watch For
COVID-19 symptoms in 2026 remain similar to prior years and overlap significantly with other circulating respiratory viruses:
- Fever or chills
- Cough and sore throat
- Runny nose or congestion
- Fatigue
- Headache
- Muscle aches
- Shortness of breath
- New loss of taste or smell (less common in recent variants)
Testing remains important for accurate diagnosis, particularly since influenza, RSV, parainfluenza, and COVID-19 can produce similar symptoms. Treatment with antivirals like Paxlovid is still recommended for high-risk individuals diagnosed with COVID-19.
What You Can Do Now
- If you are in a high-risk group and have not had a COVID-19 infection or vaccine in the past six to 12 months, talk to your doctor about whether a booster or additional protection makes sense now.
- Updated COVID-19 vaccines for the 2026–2027 season are expected to be available in late summer or early fall — high-risk individuals should plan to receive those when available.
- Continue monitoring the CDC’s weekly respiratory data updates at CDC.gov/respiratory-viruses, particularly if you live in the South or West.
- If you develop symptoms, test before attending large gatherings or visiting high-risk individuals, particularly infants, the elderly, or immunocompromised people.
- Indoor masking in crowded, high-risk settings remains an option for high-risk individuals who want additional protection during potential summer activity periods.
Cost and Access: What Patients Should Know
COVID-19 testing remains available through pharmacies, urgent care centers, and physician offices. Home antigen tests can be purchased at most pharmacies. COVID antiviral treatments like Paxlovid remain available by prescription and are covered by most insurance plans.
Updated COVID-19 vaccines are expected to be available under the ACA’s preventive services mandate with no out-of-pocket cost for most insured patients. For uninsured individuals, the CDC’s Bridge Access Program provided vaccine access in prior years; readers should check vaccines.gov for current availability.
What Happens Next
The CDC will continue updating its respiratory data page weekly. Variant surveillance data will be updated regularly through the CDC’s genomic monitoring program. Updated COVID-19 vaccine composition decisions for the 2026–2027 formulation are expected in coming months. MedicalDaily will report on any significant changes in transmission, new variant developments, or updated vaccine guidance.
The Bottom Line
COVID-19 activity is low right now. The CDC is not raising an alarm. But the agency is flagging that the South and West — where populations have less recent COVID immunity — face a heightened risk of summer activity, particularly if a variant gains traction that the immune system does not recognize as well. This is the time to check your vaccination status, know your risk profile, and monitor CDC updates — not the time for panic, but also not the time to stop paying attention.
